Skip to main content
Log in

The impact of European embryonic stem cell patent decisions on research strategies

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Recent restrictions on the patentability of human embryonic stem cell inventions in Europe necessitate a shift in R&D strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. EPO. Enlarged Board of Appeal, WARF, G02/06. (November 25, 2008).

  2. Paton, M. & Denoon, A. Eur. Intellect. Prop. Rev. 33, 590–596 (2011).

    Google Scholar 

  3. Court of Justice of the European Union, Grand Chamber, Brüstle v. Greenpeace eV, C-34/10, October 18, 2011.

  4. Moran, N. Nat. Biotechnol. 29, 1057–1059 (2011).

    Article  CAS  Google Scholar 

  5. EPO. Boards of Appeal, Technion Research and Development Foundation Ltd., T2221/10. (February 4, 2014).

  6. Mahalatchimy, A. et al. Eur. Intellect. Prop. Rev. (in the press).

  7. Harmon, S.H.E., Laurie, G. & Courtney, A. Eur. Law Rev. 38, 92–106 (2013).

    Google Scholar 

  8. Wilmut, I. Cell Stem Cell 9, 498–499 (2011).

    Article  CAS  Google Scholar 

  9. European Council. Political agreement on the 7th research framework programme: European Community (2007–2013), Brussels (European Council, 2006).

  10. Bonadio, E. Eur. Intellect. Prop. Rev. 34, 433–443 (2012).

    Google Scholar 

  11. Koch, N.J., Baum, E. & Trounson, A. Cell Stem Cell 9, 499–500 (2011).

    Article  CAS  Google Scholar 

  12. Schuster, M.I. Int. Rev. Intellect. Prop. Competition Law 43, 626–640 (2012).

    Google Scholar 

  13. Klimanskaya, I. et al. Nature 444, 481–485 (2006).

    Article  CAS  Google Scholar 

  14. US Supreme Court. Association for Molecular Pathology v. Myriad Genetics, 569 US 12–398 (June 13, 2013).

  15. German Federal Court case law, BGH, Urteil vom 27. November 2012, Az. X ZR 58/07, §31 and 43, November 27, 2012.

  16. European Patent Convention (5 October 1973; 15th edition as amended in October 2013).

Download references

Acknowledgements

We would like to thank K. Holz for her help in understanding German Federal Court case law. This work has been partially supported by REGenableMED, UK ESRC Project ES/L002779/1, and by EUCelLEX FP7 program, grant agreement no. 601806. We also thank the editors/reviewers for their constructive comments which helped us to improve the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aurélie Mahalatchimy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahalatchimy, A., Rial-Sebbag, E., Duguet, AM. et al. The impact of European embryonic stem cell patent decisions on research strategies. Nat Biotechnol 33, 41–43 (2015). https://doi.org/10.1038/nbt.3105

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3105

  • Springer Nature America, Inc.

This article is cited by

Navigation